Original-Research: The Platform Group SE & Co. KGaA (von NuWays AG): BUY
|
Original-Research: The Platform Group SE & Co. KGaA - from NuWays AG
Classification of NuWays AG to The Platform Group SE & Co. KGaA
Final FY25 out, AEP acquisition to transform the group; chg. TPG closed FY25 with a strong set of results, confirming the January prelims and coming in above the mid-point of the guidance. To recap: Revenue grew 39% yoy to € 728m, supported by broad-based growth across all five segments and eleven acquisitions completed during the year. GMV increased by ca. 44% yoy to € 1.3bn. Adj. EBITDA rose 65% yoy to € 55m, translating into a margin of 7.6% (+130bps yoy). Consumer Goods remained the group's growth engine, with revenue up 55% yoy to € 458m and adj. EBITDA up 65% to € 35.6m, accounting for 65% of group earnings. The newly established Optics & Hearing segment, added mid-year, made an immediately disproportionate earnings contribution, posting a ~25% adj. EBITDA margin in its first half-year of consolidation. All remaining segments grew both revenue and earnings yoy. FY26 guidance confirmed. Management guides for € 1.7bn GMV (eNuW: € 1.71bn), € 1.0bn revenue (eNuW: € 977m) and € 70-80m adj. EBITDA (eNuW: € 74m). The more significant story for 2026 is the pending acquisition of AEP GmbH, a B2B pharmaceutical wholesale platform generating over € 1bn in revenue. Signed in January, the deal received German Federal Cartel Office clearance at the end of March. Closing is expected by end of Q2 2026, subject to the completion of outstanding contractual conditions. Financing, to be structured as a combination of own funds and debt over a 3-5 year horizon, remains the key outstanding item, with details expected by end of May. The transformative nature of the deal is hard to overstate. Upon closing, TPG intends to bundle AEP with its existing pharma assets (ApoNow, apothekia, Doc.Green) into a standalone Pharma Group with dedicated management. On a pro-forma basis, the acquisition would lift FY26e group revenue to ~€ 2bn, adj. EBITDA to € 90-100m, and GMV to ~€ 3bn. The combined pharma segment alone is expected to generate revenues in excess of € 1.1bn and adj. EBITDA of >€ 25m. Once closed, the acquisition would hence put the company’s 2030 targets of € 3bn sales well in reach, in our view. The investment case remains fully intact, yet shares paint a different picture with an implied valuation on only 2x EV/EBITDA. In our view, the group is adequately financed and able to comfortably service its debt obligations. ND/EBITDA remains within the targeted range, op. cash flow is strong and interest obligation can comfortably be paid by operations. We confirm our BUY rating with a new € 17 PT (old: € 21) based on DCF as we trim estimates to account for the declining consumer sentiment in Germany, adjust the tax rate and a higher risk free rate. You can download the research here: the-platform-group-ag-2026-04-28-previewreview-en-c9bd4 For additional information visit our website: https://www.nuways-ag.com/research-feed Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||
2316212 28.04.2026 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 94,81 | 133,76 | 168,43 | 432,20 | 524,64 | 728,09 | 1.000,00 | |
| EBITDA1,2 | 5,88 | 1,59 | 14,11 | 46,75 | 55,63 | 71,22 | 50,00 | |
| EBITDA-Margin3 | 6,20 | 1,19 | 8,38 | 10,82 | 10,60 | 9,78 | 5,00 | |
| EBIT1,4 | 3,45 | -0,51 | 9,12 | 38,91 | 45,78 | 59,20 | 37,00 | |
| EBIT-Margin5 | 3,64 | -0,38 | 5,42 | 9,00 | 8,73 | 8,13 | 3,70 | |
| Net Profit (Loss)1 | 0,87 | -1,70 | 7,98 | 26,99 | 32,74 | 46,52 | 18,50 | |
| Net-Margin6 | 0,92 | -1,27 | 4,74 | 6,25 | 6,24 | 6,39 | 1,85 | |
| Cashflow1,7 | 5,24 | -13,81 | 2,22 | 104,09 | 57,99 | 59,72 | 55,00 | |
| Earnings per share8 | 0,14 | -0,27 | 1,12 | 1,48 | 1,60 | 2,26 | 0,90 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: RR
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| The Platform Group | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A40ZW8 | DE000A40ZW88 | SE & Co. KGaA | 66,90 Mio € | 29.10.2020 | 9F385RGG+37 | |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 7,22 | 3,81 | 1,90 | 5,00 | 0,38 | 1,12 | 0,09 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 01.07.2026 | 27.05.2026 | 20.08.2026 | 05.11.2026 | 22.04.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| -9,27% | -50,36% | -40,48% | -62,73% | -89,52% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
